Vaccine stabilizer
View Patent ↗Disclosed herein is a formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising: a tertiary amine N-oxide or a derivative thereof represented by the formulae: wherein R 1 , R 2 , and R 3 may be identical or different and each is a straight or branched lower alkyl group having from 1 to 4 carbon atoms; an inorganic salt; glutamic acid or a salt thereof; a polyol; a physiologically acceptable buffer, and a pharmaceutically acceptable carrier. The tertiary amine N-oxide may be trimethylamine-N-oxide, (CH 3 ) 3 NO. The formulation is useful for vaccine stabilization.
1. A formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising:
an inorganic salt;
glutamic acid or a salt thereof;
a polyol;
a physiologically acceptable buffer;
a pharmaceutically acceptable carrier; and
a tertiary amine N-oxide or a derivative thereof represented by the formulae:
wherein R 1 , R 2 , and R 3 may be identical or different and each is a straight or branched lower alkyl group having from 1 to 4 carbon atoms;
wherein said biological product is a vaccine comprising yellow fever virus.
2. The formulation of claim 1 , wherein the tertiary amine N-oxide is trimethylamine-N-oxide, (CH 3 ) 3 NO.
3. The formulation of claim 2 , wherein the concentration of trimethylamine-N-oxide, (CH 3 ) 3 NO, is from about 1.5 millimolar to about 800 millimolar.
4. The formulation of claim 3 , wherein the concentration of trimethylamine-N-oxide, (CH 3 ) 3 NO, is from about 2.0 millimolar to about 500 millimolar.
5. A method for stabilizing a vaccine comprising adding to the vaccine an amount of a formulation according to claim 2 , effective to stabilize the vaccine.
6. A method for administering the vaccine of claim 2 , the method comprising administering the vaccine by intramuscular injection.
7. A method for treating and/ or preventing a disease in a subject, the method comprising administering to the subject the vaccine of claim 2 , in an amount sufficient to treat or prevent the disease.
8. The formulation of claim 1 , wherein the inorganic salt is magnesium chloride, MgCl 2 .
9. The formulation of claim 8 , wherein the concentration of magnesium chloride, MgCl 2 , is from about 0.8 millimolar to about 80 millimolar.
10. The formulation of claim 9 , wherein the concentration of magnesium chloride, MgCl 2 , is from about 5 millimolar to about 50 millimolar.
11. The formulation of claim 1 , wherein the polyol is mannitol, C 6 H 8 (OH) 6 .
12. The formulation of claim 11 , wherein the concentration of mannitol, C 6 H 8 (OH) 6 , is from about 0.01 percent (w/v) to about 5 percent (w/v).
13. The formulation of claim 12 , wherein the concentration of mannitol, C 6 H 8 (OH) 6 , is from about 0.05 millimolar to about 2 millimolar.
14. The formulation of claim 1 , wherein the concentration of glutamic acid is from about 5 millimolar to about 500 millimolar.
15. The formulation of claim 14 , wherein the concentration of glutamic acid is from about 8 millimolar to about 200 millimolar.
16. The formulation of claim 1 , wherein the physiologically acceptable buffer is present in an amount effective to adjust or maintain the pH at from about 6.5 to about 8.5.
17. The formulation of claim 16 , wherein the physiologically acceptable buffer is present in an amount effective to adjust or maintain the pH at about 7.5.
18. The formulation of claim 1 , wherein the buffer is a tris buffer or a phosphate buffer.
19. A vaccine preparation comprising an antigen constituent and the formulation of claim 1 .
20. A vaccine comprising an inactivated or attenuated virus, an adjuvant, and a stabiliser comprising from about 1 millimolar to about 50 millimolar magnesium chloride, MgCl 2 ; from about 8 millimolar to about 200 millimolar glutamic acid; from about 0.05 millimolar to about 2.5 millimolar mannitol; from about one millimolar to about 500 millimolar trimethylamine-N-oxide; and an amount of a physiologically acceptable buffer effective to adjust or maintain the pH at from about 6.5 to about 8.5;
wherein said inactivated or attenuated virus is a yellow fever virus.
21. A formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising: from about one millimolar to about 200 millimolar glutamic acid, from abut 0.05 millimolar to about 5 millimolar mannitol, from about 0.01 milligram per milliliter to about 0.1 milligram per milliliter protamine, and from about 0.01 percent to about 1 percent dextrose, and an amount of a physiologically acceptable buffer effective to adjust or maintain the pH at from about 6.5 to about 8.5;
wherein said biological product is a vaccine comprising inactivated or attenuated yellow fever virus.
22. A formulation comprising: an inactivated virus or an attenuated virus; alum; trimethylamine-N-oxide; mannitol; glutamic acid; magnesium chloride, MgCl 2 ; sodium chloride; and a suitable buffer to maintain the pH of the formulation at about 7.5;
wherein said inactivated or attenuated virus is yellow fever virus.
23. The formulation of claim 22 , comprising from about 0.1 percent (w/v) to about 0.5 percent (w/v) alum; from about 1.5 millimolar to about 20 millimolar trimethylamine-N-oxide; from about 0.05 millimolar to about 2 millimolar mannitol; from about 8 millimolar to about 150 millimolar glutamic acid; and from about 100 millimolar to about 500 millimolar sodium chloride.
24. The formulation of claim 23 , comprising about 0.2 percent (w/v) alum; about 2 millimolar trimethylamine-N-oxide; from about 0.10 millimolar to about 0.20 millimolar mannitol; about 10 millimolar glutamic acid; and from about 145 millimolar to about 500 millimolar sodium chloride.